Navigation Links
Cytokinetics Reports Additional Clinical Trials Data for Ispinesib

liver, lung and lymph node metastases. The duration of response, independently reviewed, ranged from 7.1 weeks to 30.0 weeks. The median time to progression in the treated population was 5.9 weeks. The adverse events were manageable, predictable and consistent with those seen in the Phase I trials of ispinesib. The most common grade 3/4 adverse events observed were neutropenia, febrile neutropenia and neutropenic sepsis.

In addition, GSK has sponsored three dose-escalating Phase Ib clinical trials. Each of these clinical trials was designed to evaluate the safety, tolerability and pharmacokinetics of ispinesib in combination with a leading anti-cancer therapeutic, one in combination with carboplatin, the second in combination with capecitabine, and the third in combination with docetaxel. The clinical trial evaluating ispinesib in combination with capecitabine is closed to enrollment. Final data from this trial are expected in 2007.

Under a November 2006 amendment to its collaboration and license agreement with GSK, Cytokinetics has assumed responsibility for the costs and activities associated with the continued development of the KSP inhibitors, ispinesib and SB-743921, subject to GSK s option to resume responsibility for some or all development and commercialization activities associated with each of these novel drug candidates. Cytokinetics plans to conduct, at its expense, a focused development program for ispinesib in breast cancer specifically designed to supplement the broad series of Phase I and Phase II clinical trials sponsored by GSK that have demonstrated clinical activity in the treatment of patients with metastatic breast cancer and that have shown an acceptable tolerability profile for ispinesib in combination with standard chemotherapeutics.

The NCI has sponsored six additional Phase II clinical trials, evaluating the potential efficacy of ispinesib in an array of different tumor types. Enrollment has been closed for
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Cytokinetics Announces Non-clinical Data to be Presented at the 2007 AACR Annual Meeting
2. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
3. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
4. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
5. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
6. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
7. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
8. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
9. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
10. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
11. Affymax Reports Phase 2 Clinical Dose Ranging Results of Once-Per-Month Hematide for the Treatment of Anemia
Post Your Comments:
(Date:11/22/2014)... , Nov. 21, 2014 Research and Markets ... Protein Drug Industry Report, 2014-2017" report to their ... The Chinese recombinant protein drug market has been ... consumption ability and the like. During 2005-2013, sales of ... at a CAGR of 19.1%, and it is projected ...
(Date:11/21/2014)... -- Alere Inc. (NYSE: ALR ), a global ... Cunningham as Vice President, Investor Relations. In this ... communications with the investment community. "As we ... increase shareholder value, it is critical that we effectively ... Executive Officer. "We are delighted that Juliet Cunningham ...
(Date:11/21/2014)... CORONA, Calif. and VIENNA, Va. ... an innovative in-home care provider that operates in ... with BeClose, a leading provider of remote caregiving technology. Alta ... new and existing client receiving homecare services. ... believe this technology is the key to providing the ...
Breaking Medicine Technology:China Recombinant Protein Drug Industry Report, 2014-2017 2China Recombinant Protein Drug Industry Report, 2014-2017 3Alere Appoints Juliet Cunningham to Lead Investor Relations 2Alta Home Care, Inc. and BeClose Partner to Enable Seniors to Remain in Their Homes Safely and Securely 2
... 2010 Abaxis, Inc. (Nasdaq: ABAX ), ... today announced the release of a new Piccolo® reagent ... disc will be used by healthcare professionals in conjunction ... of this new panel configuration, U.S. healthcare professionals can ...
... 12, 2010 EntreMed, Inc. (Nasdaq: ... for the treatment of cancer, today reported results ... 30, 2010. (Logo: http://photos.prnewswire.com/prnh/20010620/ENMDLOGO) ... net loss for the third quarter of 2010 ...
Cached Medicine Technology:Abaxis Increases Reagent Disc Offering for Physician Office Market With Release of BioChemistry Panel Plus 2Abaxis Increases Reagent Disc Offering for Physician Office Market With Release of BioChemistry Panel Plus 3EntreMed Reports Third Quarter 2010 Financial Results 2EntreMed Reports Third Quarter 2010 Financial Results 3EntreMed Reports Third Quarter 2010 Financial Results 4
(Date:11/22/2014)... BambooFlooringChina.com is a famous brand in the bamboo ... collection of bamboo mats ; the new models are ... , According to the sales manager of BambooFlooringChina.com, Bamboo ... highly renewable resource. Their bamboo mats are 100% made from ... from natural bamboo with caramel bamboo strips. , ...
(Date:11/22/2014)... November 22, 2014 In order to provide ... promotion of cocktail party dresses. The business knows that a ... social occasions. , Now, the party dresses supplier’s ... 70% off. As the leading company in fashion industry, LunaDress ... outfit for every customer. So it always raises the professional ...
(Date:11/22/2014)... SATURDAY, Nov. 22, 2014 (HealthDay News) -- The wide ... can pose a threat for people with food allergies, ... there are so many types of food allergies that ... over the holidays," Dr. Guha Krishnaswamy, director of allergy ... said in a hospital news release. "If you ...
(Date:11/22/2014)... Recently, UWDress.com is gratified to introduce its new collection ... the company has also offered an attracting discount on ... supplier of wedding dresses, UWDress.com is good at manufacturing ... guest gowns are provided over 20 colors, which have ... is famous for high quality. Therefore, its sales increased ...
(Date:11/22/2014)... Developers and plugin specialist of Final Cut Pro ... Model bringing the impossible to FCPX from Pixel ... obj files to FCPX enabling 3d Model editing,” said Christina ... professional and armature, FCPX 3D Model is a definite game ... Cut Pro X users to upload and control 3D objects ...
Breaking Medicine News(10 mins):Health News:Trendy Bamboo Mats Online Now By BambooFlooringChina.com 2Health News:LunaDress Unveils Fabulous Cocktail Party Dresses 2Health News:'Tis the Season of Challenges for Those With Food Allergies 2Health News:Best Wedding Guest dresses Introduced by UWDress.com 2Health News:Pixel Film Studios released FCPX 3D Model plugin Exclusively for Final Cut Pro X 2
... ... and navigation enhancement XML API. , ... (PRWEB) May 27, 2010 -- Smartlogic has released a ... websites or in enterprise information management systems, using Semaphore,s search and navigation enhancement XML ...
... Helicobacter pylori , which lives in the human stomach ... like a corkscrew, or helix. For years researchers have hypothesized ... survive and thrive within the stomach,s acid-drenched environment, ... the first time, researchers at Fred Hutchinson Cancer Research Center ...
... Schrader had it all: steady job, a wife, and two ... morethat is, more children. Taking steps to keep his nuclear ... was back on the golf course the next afternoon. ... that followed Schrader would ultimately revisit the issue of having ...
... mood of those with sensitivities worsened when exposed to ... season may not mean just the inevitable coughing, sneezing ... , Researchers reported that finding at the American Psychiatric ... "Depression is a very common disorder and allergies are ...
... , ... announced that they have now added 7,000 stores in under five months of operation. The ... 100-200 new comments per day and 500 votes per day, making it one of the ... ...
... tying genes to common tumors may be invalid, researchers ... sample sizes may undercut the reliability of recent genome ... a Greek-American analysis cautions. , The observation is the ... harnessed technological innovations in so-called "whole genome sequencing" to ...
Cached Medicine News:Health News:Smartlogic Demonstrates Improved User Search, Find and Navigation with Semaphore Open Semantic Platform 2Health News:Shape matters: The corkscrew twist of H. pylori enables it to 'set up shop' in the stomach 2Health News:Shape matters: The corkscrew twist of H. pylori enables it to 'set up shop' in the stomach 3Health News:Robotic-assisted vasectomy reversal offers greater chance of fatherhood 2Health News:Allergies Might Trigger Depression 2Health News:Coupon Site TrimBack.com Adds 7000th Online Store 2Health News:Genes' Link to Certain Cancers Questioned 2
Female Mini-VEST Seamless, Front Closure...
Male Support Brief...
For Lipoplasty or surgery of abdomen, flanks and midriff...
Select Support Brief...
Medicine Products: